[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 16 of about 16
1. Dixon H, Johnston CE, Else KJ: Antigen selection for future anti-Trichuris vaccines: a comparison of cytokine and antibody responses to larval and adult antigen in a primary infection. Parasite Immunol; 2008 Sep;30(9):454-61

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antigen selection for future anti-Trichuris vaccines: a comparison of cytokine and antibody responses to larval and adult antigen in a primary infection.
  • Child anthelminthic treatment programmes are being implemented but repeated treatments are costly, may prevent the development of acquired immunity and can lead to the development of drug resistant parasites.
  • Thus, the development of a vaccine which would lead to the acquisition of immunity at an earlier age and reduce community faecal egg output would be beneficial.
  • Development of subunit vaccines requires the identification of protective antigens and their formulation in a suitable adjuvant.
  • Subcutaneous vaccination with adult excretory-secretory products (ES) protects susceptible mouse strains from T. muris.
  • Larval stages may contain novel and more relevant antigens which when incorporated in a vaccine induce worm expulsion earlier in infection than the adult worm products.
  • This study finds negligible difference in the cellular and humoral immune response to T. muris adult and third stage larva(e) (L3) ES during a primary T. muris infection, but identifies high molecular weight proteins in both adult and L3 ES as potential vaccine candidates.
  • [MeSH-minor] Animals. Antibodies, Helminth / blood. Antibodies, Helminth / immunology. Immunoglobulin G / blood. Immunoglobulin G / immunology. Larva / immunology. Mice. Mice, Inbred AKR. Mice, Inbred BALB C. Vaccines / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18565148.001).
  • [ISSN] 1365-3024
  • [Journal-full-title] Parasite immunology
  • [ISO-abbreviation] Parasite Immunol.
  • [Language] eng
  • [Grant] United Kingdom / Wellcome Trust / / 068028
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Helminth; 0 / Antigens, Helminth; 0 / Cytokines; 0 / Immunoglobulin G; 0 / Vaccines
  •  go-up   go-down


2. Brito JC, da Nóbrega PV, Guedes Filho GE, Santos FJ, Souto MG: [Transverse myelopathy in an adult with acute lymphoblastic leukemia: case report]. Arq Neuropsiquiatr; 2001 Jun;59(2-A):272-5
MedlinePlus Health Information. consumer health - Spinal Cord Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Transverse myelopathy in an adult with acute lymphoblastic leukemia: case report].
  • [Transliterated title] Mielopatia transversa em adulto portador de leucemia aguda linfoblástica: relato de caso.
  • We report a case of transverse myelopathy in a 31 year old white man with acute lymphoblastic leukemia, subtype L3 (ALL-L3).
  • This is a severe form of leukemia that affects children more often than adults.
  • The etiologic diagnostic was obtained through peripheral blood study, bone marrow cytology, cerebrospinal fluid analysis and magnetic resonance image of the dorsal cord.
  • The antileukemic treatment with specific drugs had no influence on the fatal outcome of the disease.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Spinal Cord Diseases / etiology
  • [MeSH-minor] Acute Disease. Adult. Fatal Outcome. Humans. Male

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11400042.001).
  • [ISSN] 0004-282X
  • [Journal-full-title] Arquivos de neuro-psiquiatria
  • [ISO-abbreviation] Arq Neuropsiquiatr
  • [Language] por
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


3. Wang Z, Abubucker S, Martin J, Wilson RK, Hawdon J, Mitreva M: Characterizing Ancylostoma caninum transcriptome and exploring nematode parasitic adaptation. BMC Genomics; 2010;11:307
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To better understand hookworm biology and nematode parasitism, the present study generated a near complete transcriptome of the canine hookworm Ancylostoma caninum to a very high coverage using high throughput technology, and compared it to those of the free-living nematode Caenorhabditis elegans and the parasite Brugia malayi.
  • RESULTS: The generated transcripts from four developmental stages, infective L3, serum stimulated L3, adult male and adult female, covered 93% of the A. caninum transcriptome.
  • Examining the developmental expression profiles of A. caninum revealed major transitions in gene expression from larval stages to adult.
  • Adult males expressed the highest number of selectively expressed genes, but adult female expressed the highest number of selective parasitism-related genes.
  • Parasitism related genes were expressed more selectively in adult male and female worms.
  • The comprehensive analysis of digital expression profiles along with transcriptome comparisons enabled identification of a set of parasitism genes encoding secretory proteins in animal parasitic nematode.
  • CONCLUSIONS: This study validated the usage of deep sequencing for gene expression profiling.
  • This comprehensive comparative genomic and expression study substantially improves our understanding of the basic biology and parasitism of hookworms and, is expected, in the long run, to accelerate research toward development of vaccines and novel anthelmintics.
  • [MeSH-major] Adaptation, Biological / genetics. Ancylostoma / genetics. Ancylostoma / parasitology. Gene Expression Profiling
  • [MeSH-minor] Animals. Dogs. Female. Male. Polymorphism, Single Nucleotide. Selection, Genetic. Vaccines

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Methods Mol Biol. 2009;533:153-87 [19277558.001]
  • [Cites] BMC Genomics. 2009;10:22 [19144180.001]
  • [Cites] Nat Genet. 1999 Jul;22(3):231-8 [10391209.001]
  • [Cites] Nat Genet. 2004 Dec;36(12):1259-67 [15543149.001]
  • [Cites] BMC Bioinformatics. 2004 Nov 30;5:187 [15571632.001]
  • [Cites] BMC Genomics. 2005;6:58 [15854223.001]
  • [Cites] Infect Immun. 2006 Feb;74(2):961-7 [16428741.001]
  • [Cites] Lancet. 2006 May 6;367(9521):1521-32 [16679166.001]
  • [Cites] BMC Bioinformatics. 2007;8:41 [17284313.001]
  • [Cites] Science. 2007 Sep 21;317(5845):1756-60 [17885136.001]
  • [Cites] Clin Infect Dis. 2008 Jan 15;46(2):282-8 [18171264.001]
  • [Cites] Acta Trop. 1999 Oct 15;73(3):243-9 [10546842.001]
  • [Cites] Parasitol Today. 1999 May;15(5):188-93 [10322352.001]
  • [Cites] Nat Genet. 1999 Dec;23(4):452-6 [10581034.001]
  • [Cites] Int J Parasitol. 2000 Apr 10;30(4):347-55 [10731559.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3029-33 [11248026.001]
  • [Cites] Bioinformatics. 2001 Sep;17(9):847-8 [11590104.001]
  • [Cites] Mol Biochem Parasitol. 2002 Mar;120(1):1-21 [11849701.001]
  • [Cites] Mol Biochem Parasitol. 2002 Apr 9;120(2):291-6 [11897134.001]
  • [Cites] Cell Mol Life Sci. 2002 Feb;59(2):349-62 [11915948.001]
  • [Cites] FASEB J. 2002 Sep;16(11):1458-60 [12205047.001]
  • [Cites] J Parasitol. 2003 Apr;89(2):402-7 [12760667.001]
  • [Cites] Int J Parasitol. 2003 Aug;33(9):897-907 [12906874.001]
  • [Cites] Trends Parasitol. 2003 Dec;19(12):547-51 [14642761.001]
  • [Cites] J Mol Biol. 2004 May 14;338(5):1027-36 [15111065.001]
  • [Cites] Int J Parasitol. 2004 Jul;34(8):909-14 [15217729.001]
  • [Cites] J Parasitol. 1968 Jun;54(3):426-9 [5761146.001]
  • [Cites] Theor Popul Biol. 1975 Apr;7(2):256-76 [1145509.001]
  • [Cites] Annu Rev Physiol. 1981;43:323-41 [7011187.001]
  • [Cites] Mol Biol Evol. 1986 Sep;3(5):418-26 [3444411.001]
  • [Cites] J Parasitol. 1991 Aug;77(4):587-91 [1713962.001]
  • [Cites] J Biol Chem. 1996 Mar 22;271(12):6672-8 [8636085.001]
  • [Cites] Pediatr Res. 1996 Oct;40(4):515-21 [8888276.001]
  • [Cites] Nature. 1997 May 29;387(6632):489-93 [9168109.001]
  • [Cites] Biochem J. 1997 Jul 1;325 ( Pt 1):129-37 [9224638.001]
  • [Cites] Genome Res. 1997 Oct;7(10):986-95 [9331369.001]
  • [Cites] Nature. 1998 Mar 5;392(6671):71-5 [9510248.001]
  • [Cites] Genome Res. 1998 Jun;8(6):590-8 [9647634.001]
  • [Cites] Science. 1998 Dec 11;282(5396):2012-8 [9851916.001]
  • [Cites] Science. 1998 Dec 11;282(5396):2041-6 [9851921.001]
  • [Cites] Bioinformatics. 1998;14(9):755-63 [9918945.001]
  • [Cites] Mol Biochem Parasitol. 1999 Apr 30;99(2):149-65 [10340481.001]
  • [Cites] Nucleic Acids Res. 2008 Jan;36(Database issue):D480-4 [18077471.001]
  • [Cites] Mol Biochem Parasitol. 2008 Feb;157(2):187-92 [18082904.001]
  • [Cites] PLoS Negl Trop Dis. 2008;2(1):e130 [18235850.001]
  • [Cites] PLoS Negl Trop Dis. 2008;2(10):e326 [18958170.001]
  • [Cites] Nat Rev Drug Discov. 2008 Nov;7(11):900-7 [18927591.001]
  • [Cites] Nucleic Acids Res. 2009 Jan;37(Database issue):D571-8 [18940860.001]
  • [Cites] Nucleic Acids Res. 2009 Jan;37(1):289-97 [19042974.001]
  • [Cites] BMC Evol Biol. 2009;9:23 [19175938.001]
  • [Cites] BMC Genomics. 2009;10:114 [19296854.001]
  • (PMID = 20470405.001).
  • [ISSN] 1471-2164
  • [Journal-full-title] BMC genomics
  • [ISO-abbreviation] BMC Genomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Vaccines
  • [Other-IDs] NLM/ PMC2882930
  •  go-up   go-down


Advertisement
4. Simcock DC, Brown S, Neale JD, Przemeck SM, Simpson HV: L3 and adult Ostertagia (Teladorsagia) circumcincta exhibit cyanide sensitive oxygen uptake. Exp Parasitol; 2006 Jan;112(1):1-7
Hazardous Substances Data Bank. OXYGEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] L3 and adult Ostertagia (Teladorsagia) circumcincta exhibit cyanide sensitive oxygen uptake.
  • Oxygen consumption by L3 and adult Ostertagia (Teladorsagia) circumcincta was examined in vitro to determine whether oxygen can be utilised in metabolism.
  • Rates of consumption (in nmol O2/h/1000 worms) were 13+/-1 in sheathed L3, 34+/-6 in ex-sheathed L3, and 1944+/-495 in adult worms.
  • Consumption was inhibited 95% by cyanide in L3 and 74% in adults.
  • Oxygen concentration in abomasal fluid varied between 10 and 30 microM in both infected and uninfected animals.
  • [MeSH-major] Abomasum / chemistry. Ostertagia / metabolism. Ostertagiasis / veterinary. Oxygen Consumption / drug effects. Potassium Cyanide / pharmacology. Sheep Diseases / parasitology
  • [MeSH-minor] Aerobiosis. Animals. Glucose / pharmacology. Hydrogen-Ion Concentration. Larva / metabolism. Oxygen / analysis. Sheep

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. POTASSIUM CYANIDE .
  • Hazardous Substances Data Bank. GLUCOSE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16198342.001).
  • [ISSN] 0014-4894
  • [Journal-full-title] Experimental parasitology
  • [ISO-abbreviation] Exp. Parasitol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] IY9XDZ35W2 / Glucose; MQD255M2ZO / Potassium Cyanide; S88TT14065 / Oxygen
  •  go-up   go-down


5. Jiang XJ, Wang JS, Fang Q: [Gene expression of breast cancer resistance protein in adult acute lymphocytic leukemia and its clinical significance]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Feb;16(1):31-4
Genetic Alliance. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gene expression of breast cancer resistance protein in adult acute lymphocytic leukemia and its clinical significance].
  • The objective of this study was to investigate the relationship between the expressions of breast cancer resistance protein (BCRP) gene and drug resistance as well as prognosis in adult patients with acute lymphocytic leukemia (ALL).
  • Semi-quantitative reverse transcriptase polymerase chain reaction (RT-PCR) was used to detect the expression of BCRP gene in 97 adult patients with acute lymphocytic leukemia (ALL) and 30 normal subjects.
  • In ALL subtypes BCRP gene expression of L3 type was distinctly higher than that of L(1), L(2) types.
  • In immune types the BCRP gene expression of B-ALL was higher than that of T cell type, especially in mature B cell type with obviously statistical significance (p<0.01).
  • It is concluded that the high expression of BCRP gene may induce clinical drug resistance, and may be an unfavorable factor for prognosis in adult patients with acute lymphocytic leukemia.
  • [MeSH-major] ATP-Binding Cassette Transporters / metabolism. Drug Resistance, Neoplasm / genetics. Neoplasm Proteins / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] ATP Binding Cassette Transporter, Sub-Family G, Member 2. Adolescent. Adult. Aged. Female. Humans. Male. Middle Aged. Prognosis. Reverse Transcriptase Polymerase Chain Reaction. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18315895.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / ABCG2 protein, human; 0 / ATP Binding Cassette Transporter, Sub-Family G, Member 2; 0 / ATP-Binding Cassette Transporters; 0 / Neoplasm Proteins
  •  go-up   go-down


6. Barnes EH, Dobson RJ, Stein PA, Le Jambre LF, Lenane IJ: Selection of different genotype larvae and adult worms for anthelmintic resistance by persistent and short-acting avermectin/milbemycins. Int J Parasitol; 2001 May 15;31(7):720-7
MedlinePlus Health Information. consumer health - Antibiotics.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Selection of different genotype larvae and adult worms for anthelmintic resistance by persistent and short-acting avermectin/milbemycins.
  • To understand the factors that influence selection for anthelmintic resistance, it is necessary to examine the impact of drug treatment, particularly persistent drugs, on all phases of the worm life cycle.
  • The efficacy of various avermectin/milbemycin anthelmintics was determined against resident worms, incoming larvae (L3) and development of eggs in faecal culture.
  • Selection for resistance by IVM capsules occurred at the adult and L3 stages because of poor efficacy against these stages for all resistant genotypes.
  • However, the selective advantage of these surviving worms was reduced due to the low development of their eggs to L3 in faecal culture.
  • For MOX, selection for resistance predominantly occurred after treatment because of high efficacy against resident adult worms of all resistant genotypes but poor efficacy against resistant L3 ingested after drug administration.
  • Mean IVM efficacies against homozygous and heterozygous resistant adult worms were not different, and IVM capsule efficacy against incoming L3 was approximately 70% for all resistant genotypes, consistent with a dominant trait.
  • MOX was highly effective against adults of all resistant genotypes and approximately 76% effective against incoming L3 regardless of resistance genotype, also consistent with a dominant trait.
  • These results will enable the impact of persistent drugs on worm control and anthelmintic resistance to be estimated.
  • [MeSH-major] Anthelmintics / administration & dosage. Anti-Bacterial Agents / administration & dosage. Drug Resistance / genetics. Haemonchiasis / veterinary. Haemonchus / genetics. Ivermectin / administration & dosage. Ivermectin / analogs & derivatives. Sheep Diseases / drug therapy
  • [MeSH-minor] Administration, Oral. Animals. Delayed-Action Preparations. Female. Genotype. Larva / genetics. Macrolides. Male. Sheep

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11336754.001).
  • [ISSN] 0020-7519
  • [Journal-full-title] International journal for parasitology
  • [ISO-abbreviation] Int. J. Parasitol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anthelmintics; 0 / Anti-Bacterial Agents; 0 / Delayed-Action Preparations; 0 / Macrolides; 51570-36-6 / milbemycin; 70288-86-7 / Ivermectin; 73989-17-0 / avermectin
  •  go-up   go-down


7. Duffy MS, MacAfee N, Burt MD, Appleton JA: An aspartyl protease inhibitor orthologue expressed by Parelaphostrongylus tenuis is immunogenic in an atypical host. Clin Diagn Lab Immunol; 2002 Jul;9(4):763-70
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This parasite is the causative agent of a debilitating neurologic disease in atypical hosts, including domestic livestock.
  • In order to identify proteins of potential significance in the host-parasite relationship, a cDNA library was produced from adult P. tenuis mRNA.
  • Antibody that was generated against this recombinant protein of P. tenuis (Pt-API-1) detected the native protein in E/S products, in muscle and gonad, and on the surface of the cuticle of adult male and female P. tenuis.
  • The native protein was detected in internal structures of first-stage (L1) and third-stage (L3) larvae.
  • Reverse transcription-PCR confirmed expression of Pt-api-1 in L1, L3, and adult male and female worms.
  • Responses were sustained or biphasic in animals with patent infections, consistent with expression of Pt-API-1 by L1.
  • [MeSH-minor] Amino Acid Sequence. Animals. Antibodies, Helminth / blood. DNA, Helminth / analysis. Female. Gene Library. Male. Molecular Sequence Data. Protease Inhibitors / chemistry. Protease Inhibitors / immunology. Sequence Alignment. Strongylida Infections / parasitology. Strongylida Infections / veterinary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Wildl Dis. 1985 Oct;21(4):454-5 [3841163.001]
  • [Cites] J Wildl Dis. 1980 Oct;16(4):533-40 [7463606.001]
  • [Cites] J Reprod Fertil Suppl. 1987;35:379-88 [3479592.001]
  • [Cites] Anal Biochem. 1987 Nov 1;166(2):368-79 [2449095.001]
  • [Cites] J Exp Med. 1988 Apr 1;167(4):1505-10 [3356969.001]
  • [Cites] Immunology. 1990 May;70(1):126-32 [2354857.001]
  • [Cites] Biochemistry. 1990 Aug 14;29(32):7366-72 [2223768.001]
  • [Cites] J Wildl Dis. 1992 Jan;28(1):95-101 [1548808.001]
  • [Cites] Eur J Immunol. 1992 Jun;22(6):1519-24 [1601038.001]
  • [Cites] Trop Med Parasitol. 1992 Sep;43(3):139-45 [1281926.001]
  • [Cites] Mol Biochem Parasitol. 1993 Feb;57(2):349-51 [8433724.001]
  • [Cites] Mol Biochem Parasitol. 1993 Nov;62(1):143-6 [8114819.001]
  • [Cites] Parasite Immunol. 1994 Jun;16(6):297-303 [7970866.001]
  • [Cites] J Immunol. 1995 Aug 1;155(3):1316-25 [7543519.001]
  • [Cites] J Parasitol. 1998 Dec;84(6):1231-6 [9920319.001]
  • [Cites] Parasitology. 1996 Mar;112 ( Pt 3):331-8 [8728997.001]
  • [Cites] Annu Rev Immunol. 1997;15:505-33 [9143698.001]
  • [Cites] Am J Trop Med Hyg. 1997 Nov;57(5):626-33 [9392607.001]
  • [Cites] Exp Parasitol. 1998 Mar;88(3):200-9 [9562423.001]
  • [Cites] J Wildl Dis. 1999 Oct;35(4):783-5 [10574541.001]
  • [Cites] Nat Struct Biol. 2000 Aug;7(8):653-7 [10932249.001]
  • [Cites] J Wildl Dis. 2002 Apr;38(2):448-52 [12038147.001]
  • [Cites] J Parasitol. 2002 Jun;88(3):587-93 [12099432.001]
  • [Cites] Pathol Vet. 1965;2(4):360-79 [5853593.001]
  • [Cites] Can J Zool. 1966 Sep;44(5):889-94 [5950662.001]
  • [Cites] Can J Comp Med. 1969 Oct;33(4):280-6 [4243034.001]
  • [Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]
  • [Cites] J Immunol Methods. 1986 Feb 12;86(2):217-23 [3511153.001]
  • (PMID = 12093670.001).
  • [ISSN] 1071-412X
  • [Journal-full-title] Clinical and diagnostic laboratory immunology
  • [ISO-abbreviation] Clin. Diagn. Lab. Immunol.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ AF277291
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Helminth; 0 / DNA, Helminth; 0 / Protease Inhibitors; EC 3.4.23.- / Aspartic Acid Endopeptidases
  • [Other-IDs] NLM/ PMC120043
  •  go-up   go-down


8. Lee EJ, Petroni GR, Schiffer CA, Freter CE, Johnson JL, Barcos M, Frizzera G, Bloomfield CD, Peterson BA: Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251. J Clin Oncol; 2001 Oct 15;19(20):4014-22
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
  • PURPOSE: To define the activity and feasibility of brief-duration high-intensity chemotherapy for adults with small noncleaved, non-Hodgkin's lymphoma (SNC) and the L3 variant of acute lymphocytic leukemia (L3 ALL).
  • PATIENTS AND METHODS: Seventy-five adults with either SNC or L3 ALL (median age, 44 years) were treated with an aggressive regimen that consisted of one cycle of cyclophosphamide and prednisone followed by cycles containing either ifosfamide or cyclophosphamide; high-dose methotrexate, vincristine, dexamethasone, and either doxorubicin or etoposide/cytarabine; or intrathecal triple therapy with prophylactic CNS irradiation.
  • RESULTS: All 24 patients with L3 ALL and the 30 of 51 patients with SNC confirmed by central histologic review were included in this analysis.
  • Responses and toxicities were similar in the patients with both lymphoma and leukemia.
  • CONCLUSION: Aggressively delivered chemotherapy is potentially curative in as many as half of patients with SNC and the L3 ALL variant.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adult. Aged. Central Nervous System. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Drug Administration Schedule. Etoposide / administration & dosage. Female. Humans. Ifosfamide / therapeutic use. Infection / chemically induced. Injections, Spinal. Male. Methotrexate / administration & dosage. Neutropenia / chemically induced. Prednisone / administration & dosage. Survival Analysis. Thrombocytopenia / chemically induced. Vincristine / administration & dosage

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11600602.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA31946
  • [Publication-type] Clinical Trial; Journal Article; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; UM20QQM95Y / Ifosfamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate
  • [Number-of-references] 16
  •  go-up   go-down


9. Colović M, Bogdanović A, Janković G, Kraguljac N, Suvajdzić N: Long-term survival in acute lymphoblastic leukaemia in adults treated according to the LALA 87 protocol. Chemotherapy; 2003 Jun;49(3):138-45
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival in acute lymphoblastic leukaemia in adults treated according to the LALA 87 protocol.
  • BACKGROUND: Between January 1989 and July 1995, a prospective study of the therapeutic efficacy of the LALA 87 protocol in adult acute lymphoblastic leukaemia (ALL) has been conducted.
  • The median age of the patients was 40 years (range: 15-65), the gender ratio (M/F) was 66/46, and the morphologic FAB (French-American-British) profile was L1 in 30 (26.9%) patients, L2 in 71 (63.3%) and L3 morphology in 11 (9.8%) of the patients.
  • Maintenance therapy was given for 2 years and consisted of different drugs as reinforcement, daily 6-mercaptopurine and weekly methotrexate.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] 6-Mercaptopurine / administration & dosage. Administration, Oral. Adolescent. Adult. Age Factors. Aged. Central Nervous System Neoplasms / prevention & control. Cyclophosphamide / administration & dosage. Daunorubicin / administration & dosage. Disease-Free Survival. Female. Humans. Infusions, Intravenous. Male. Methotrexate / administration & dosage. Middle Aged. Prednisone / administration & dosage. Prognosis. Treatment Outcome. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 S. Karger AG, Basel
  • (PMID = 12815207.001).
  • [ISSN] 0009-3157
  • [Journal-full-title] Chemotherapy
  • [ISO-abbreviation] Chemotherapy
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; E7WED276I5 / 6-Mercaptopurine; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


10. McVeigh P, Leech S, Marks NJ, Geary TG, Maule AG: Gene expression and pharmacology of nematode NLP-12 neuropeptides. Int J Parasitol; 2006 May 31;36(6):633-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DYRPLQFamide (1 nM-10 microM; n > or =6) produced contraction of innervated dorsal and ventral Ascaris body wall muscle preparations (10 microM, 6.8+/-1.9 g; 1 microM, 4.6+/-1.8 g; 0.1 microM, 4.1+/-2.0 g; 10 nM, 3.8+/-2.0 g; n > or =6), and also caused a qualitatively similar, but quantitatively lower contractile response (10 microM, 4.0+/-1.5 g, n=6) on denervated muscle strips.
  • Transcription was also identified in both L3 and adult stages of T. colubriformis, in which Tc-nlp-12 is expressed in a single tail neurone.
  • Conversely, As-nlp-12 is expressed in both head and tail tissue of adult female A. suum, suggesting species-specific differences in the transcription pattern of this gene.
  • [MeSH-major] Caenorhabditis elegans Proteins / metabolism. Helminth Proteins / metabolism. Nematoda / metabolism. Neuropeptides / metabolism
  • [MeSH-minor] Amino Acid Sequence. Animals. Ascaris suum / genetics. Ascaris suum / metabolism. Ascaris suum / physiology. Caenorhabditis elegans / genetics. Caenorhabditis elegans / metabolism. Caenorhabditis elegans / physiology. DNA, Complementary / genetics. DNA, Helminth / genetics. Dose-Response Relationship, Drug. Female. Gene Expression. Male. Molecular Sequence Data. Muscle Contraction / drug effects. Muscle Contraction / physiology. Tissue Culture Techniques. Transcription, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16600246.001).
  • [ISSN] 0020-7519
  • [Journal-full-title] International journal for parasitology
  • [ISO-abbreviation] Int. J. Parasitol.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ AY347872/ DQ186899
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Caenorhabditis elegans Proteins; 0 / DNA, Complementary; 0 / DNA, Helminth; 0 / Helminth Proteins; 0 / Neuropeptides; 0 / aspartyl-tyrosyl-arginyl-prolyl-leucyl-glutaminyl-phenylalaninamide
  •  go-up   go-down


11. Murthy PK, Dixit S, Gaur RL, Kumar R, Sahoo MK, Shakya N, Joseph SK, Palne S, Gupta S: Influence of Brugia malayi life stages and BmAFII fraction on experimental Leishmania donovani infection in hamsters. Acta Trop; 2008 May;106(2):81-9
Hazardous Substances Data Bank. NITRIC OXIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The influence of live Brugia malayi parasites and a Sephadex G-200 fraction of the adult parasite extract (BmAFII) on the progression of Leishmania donovani infection was studied.
  • Inbred hamsters were first infected with B. malayi infective 3rd stage larvae (L3), adult worms or microfilariae (mf), and then with L. donovani amastigotes (Ld), or vice versa or received both the infections simultaneously; a group of animals were first immunized with BmAFII and then infected with Ld. L. donovani parasite burden was determined between 17 and 19 days post amastigote challenge (p.a.c.) and, in case of immunized animals, between 32 and 35 days p.a.c also.
  • Nitric oxide (NO) release from peritoneal macrophages and cellular proliferative responses of lymphnode cells were assessed in BmAFII-immunized animals given leishmania infection or no infection.
  • Leishmanial parasite burden was significantly reduced in animals exposed to filarial L3 before amastigote inoculation and in animals given filarial adult worms after or together with amastigotes.
  • Prior immunization of leishmania-infected animals with BmAFII also reduced the leishmanial parasite burden (17-19 days p.a.c.: >90%; 32-35 days p.a.c.: 60%).
  • These animals showed upregulation of NO release and cellular proliferative responses to promastigote antigen or BmAFII stimulation in vitro.
  • The findings show, for the first time, that B. malayi L3/adult worms or immunization with BmAFII inhibits progression of L. donovani infection in hamsters and this is associated with upregulation of NO and lymphocyte proliferative responses indicating that Th1 response might be responsible for this.
  • [MeSH-minor] Animals. Cell Proliferation. Cricetinae. Lymph Nodes / immunology. Lymphocytes / immunology. Macrophages, Peritoneal / immunology. Male. Nitric Oxide / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18329620.001).
  • [ISSN] 0001-706X
  • [Journal-full-title] Acta tropica
  • [ISO-abbreviation] Acta Trop.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antigens, Helminth; 31C4KY9ESH / Nitric Oxide
  •  go-up   go-down


12. Huber A, Prosl H, Joachim A, Simpson HV, Pedley KC: Effects of excretory/secretory products of Haemonchus contortus on cell vacuolation. Parasitol Res; 2005 Jul;96(5):290-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of excretory/secretory products of Haemonchus contortus on cell vacuolation.
  • Excretory/secretory (ES) products of the gastric nematode, Haemonchus contortus, have been implicated in the inhibition of gastric acid secretion which follows infection.
  • Parietal cell vacuolation has been observed in abomasal sections from parasitised sheep, and ES prepared in vitro has been reported to cause vacuolation and to increase neutral red (NR) uptake in epithelial cell cultures.
  • We have used the latter approach to examine, at the cellular level, the effects of ES prepared from L3 and adult nematodes.
  • Both NR uptake and cellular vacuolation were increased following exposure to larval or adult ES products.
  • ES preparations from adult worms induced more extensive vacuolation then those from L3 worms and, as with VacA treatment, adherent cells remained viable despite high levels of vacuolation.
  • Whereas VacA-induced vacuolation resulted in NR uptake predominantly localised in vacuoles, this appeared not to be the case with ES-induced vacuolation, suggesting that different mechanisms might be involved.
  • Both ES and VacA exposure was associated with an increased rate of cell detachment.
  • [MeSH-major] Biological Factors / pharmacology. Epithelial Cells / drug effects. Haemonchus / metabolism. Helminth Proteins / pharmacology. Vacuoles / drug effects
  • [MeSH-minor] Abomasum / parasitology. Animals. HeLa Cells. Humans. Larva / metabolism. Sheep

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem Pharmacol. 1974 Sep 15;23 (18):2495-531 [4606365.001]
  • [Cites] Int J Parasitol. 1985 Apr;15(2):159-65 [3997348.001]
  • [Cites] J Infect Dis. 1990 Jun;161(6):1302-4 [2345308.001]
  • [Cites] Int J Parasitol. 1997 Jul;27(7):825-31 [9279586.001]
  • [Cites] J Parasitol. 1986 Apr;72(2):339-45 [3734999.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Aug 19;262(1):245-50 [10448099.001]
  • [Cites] Infect Immun. 1996 Oct;64(10):4197-203 [8926088.001]
  • [Cites] Exp Parasitol. 1982 Dec;54(3):371-8 [6891337.001]
  • [Cites] Infect Immun. 1998 Aug;66(8):3981-4 [9673292.001]
  • [Cites] Int J Parasitol. 1996 Oct;26(10):1063-74 [8982786.001]
  • [Cites] J Exp Med. 1994 May 1;179(5):1653-58 [8163943.001]
  • [Cites] J Physiol Pharmacol. 1993 Mar;44(1):17-22 [8518421.001]
  • [Cites] Vet Parasitol. 2002 Mar 20;104(3):243-55 [11812622.001]
  • [Cites] Vet J. 2000 May;159(3):238-51 [10775468.001]
  • [Cites] Am J Physiol. 1997 Jan;272(1 Pt 1):C48-58 [9038810.001]
  • [Cites] Gut. 1992 Dec;33(12):1612-6 [1487161.001]
  • [Cites] J Parasitol. 1996 Apr;82(2):197-202 [8604083.001]
  • [Cites] Appl Biochem Biotechnol. 1991 Jul;30(1):29-41 [1952924.001]
  • [Cites] Vet Parasitol. 2000 Mar 28;89(1-2):79-94 [10729648.001]
  • [Cites] N Z Vet J. 1999 Feb;47(1):20-4 [16032062.001]
  • [Cites] Infect Immun. 1991 Apr;59(4):1264-70 [2004808.001]
  • [Cites] Vet Parasitol. 2002 Mar 20;104(3):217-28 [11812620.001]
  • [Cites] J Biotechnol. 1996 May 15;46(3):161-85 [8672289.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2000 Aug;279(2):G400-10 [10915650.001]
  • [Cites] Infect Immun. 1998 Jun;66(6):2943-50 [9596771.001]
  • [Cites] J Clin Pathol. 1988 May;41(5):597 [3384991.001]
  • [Cites] J Parasitol. 1963 Aug;49:698-9 [14050253.001]
  • [Cites] Am J Physiol. 1990 May;258(5 Pt 1):G719-27 [2159239.001]
  • [Cites] J Cell Biol. 1981 Sep;90(3):656-64 [7287819.001]
  • [Cites] Am J Vet Res. 1981 Mar;42(3):498-502 [7271014.001]
  • [Cites] Gut. 1996 Dec;39(6):795-9 [9038659.001]
  • [Cites] Parasitol Res. 2005 Feb;95(3):213-7 [15723269.001]
  • [Cites] Scand J Gastroenterol. 1996 May;31(5):428-33 [8734337.001]
  • [Cites] J Med Microbiol. 1988 Jun;26(2):93-9 [3385767.001]
  • [Cites] Infect Immun. 1996 Jul;64(7):2829-33 [8698518.001]
  • [Cites] Infect Immun. 1990 Jun;58(6):1992-4 [2341188.001]
  • [Cites] Vet Parasitol. 1996 Apr;62(3-4):291-305 [8686175.001]
  • [Cites] Cancer Res. 2003 Mar 1;63(5):951-7 [12615708.001]
  • [Cites] Infect Immun. 1999 Aug;67(8):4237-42 [10417197.001]
  • [Cites] J Clin Invest. 1998 Aug 15;102(4):813-20 [9710450.001]
  • (PMID = 15918071.001).
  • [ISSN] 0932-0113
  • [Journal-full-title] Parasitology research
  • [ISO-abbreviation] Parasitol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biological Factors; 0 / Helminth Proteins
  •  go-up   go-down


13. Paolini V, Fouraste I, Hoste H: In vitro effects of three woody plant and sainfoin extracts on 3rd-stage larvae and adult worms of three gastrointestinal nematodes. Parasitology; 2004 Jul;129(Pt 1):69-77
MedlinePlus Health Information. consumer health - Herbal Medicine.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro effects of three woody plant and sainfoin extracts on 3rd-stage larvae and adult worms of three gastrointestinal nematodes.
  • Because some in vivo results indicated that the effects of tannins differed depending on the parasitic species and/or stages, the effects were measured on 3rd-stage larvae (L3) and adult worms of Teladorsagia circumcincta, Haemonchlus contortus and Trichostrongylus colubriformis.
  • Effects of sainfoin extracts were significant on T. colubriformis and H. contortus L3, and on abomasal adult worms.
  • Without PEG, significant inhibitory effects on L3 and adult worms were confirmed.
  • After addition of PEG, the larval migration and motility of adult worms were restored in most cases.
  • [MeSH-major] Corylus / chemistry. Goat Diseases / drug therapy. Goat Diseases / parasitology. Phytotherapy / veterinary. Quercus / chemistry. Tannins / pharmacology. Trichostrongyloidea / growth & development. Trichostrongyloidiasis / drug therapy. Trichostrongyloidiasis / veterinary
  • [MeSH-minor] Animals. Biological Assay. Fabaceae / chemistry. Goats. Plant Leaves / chemistry. Polyethylene Glycols / pharmacology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15267113.001).
  • [ISSN] 0031-1820
  • [Journal-full-title] Parasitology
  • [ISO-abbreviation] Parasitology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Tannins; 30IQX730WE / Polyethylene Glycols
  •  go-up   go-down


14. Giménez-Pardo C, Martínez-Grueiro MM, Gómez-Barrio A, Rodríguez-Caabeiro F: Cholinesterase and phosphatase activities in adults and infective-stage larvae of levamisole-resistant and levamisole-susceptible isolates of Haemonchus contortus. Vet Res Commun; 2003 Dec;27(8):611-23

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cholinesterase (ChE) and acid phosphatase (AP) activities, but not alkaline phosphatase activities, were detected in cytosolic and membrane-bound fractions of adult and infective-stage larvae of levamisole-resistant and levamisole-susceptible Haemonchus contortus.
  • In contrast to other gastrointestinal nematodes, the ChE activity was higher in L3 than in adults and, in both cases, was mainly associated with membranes.
  • Differences between resistant and susceptible L3 were observed in the response to inhibitors (cytosolic fraction) and in the enzymatic content (membrane-bound fraction).
  • Phosphatase activity was detected at acidic pH in all fractions, being higher in the adult than in the L3 stage.
  • [MeSH-minor] Animals. Benzenaminium, 4,4'-(3-oxo-1,5-pentanediyl)bis(N,N-dimethyl-N-2-propenyl-), Dibromide / pharmacology. Cholinesterase Inhibitors / pharmacology. Cytosol / enzymology. Drug Resistance. Larva / enzymology. Octoxynol / pharmacology. Tetraisopropylpyrophosphamide / pharmacology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dev Biol. 1991 Sep;147(1):133-43 [1652526.001]
  • [Cites] Int J Parasitol. 1996 May;26(5):499-508 [8818729.001]
  • [Cites] J Biol Chem. 1996 May 3;271(18):10973-83 [8631917.001]
  • [Cites] Biochem Pharmacol. 1963 Nov;12:1241-52 [14078913.001]
  • [Cites] J Parasitol. 2000 Feb;86(1):1-6 [10701555.001]
  • [Cites] Parasitology. 1980 Feb;80(1):23-38 [7383707.001]
  • [Cites] Exp Parasitol. 1975 Aug;38(1):75-82 [1171024.001]
  • [Cites] Comp Biochem Physiol C. 1992 Sep;103(1):129-34 [1360365.001]
  • [Cites] Ann Clin Biochem. 1992 Nov;29 ( Pt 6):659-62 [1489162.001]
  • [Cites] Int J Parasitol. 1994 Jul;24(4):501-10 [8082980.001]
  • [Cites] Int J Parasitol. 1973 Sep;3(5):599-608 [4741635.001]
  • [Cites] Parasitology. 1971 Jun;62(3):367-73 [5104618.001]
  • [Cites] Adv Enzymol Relat Areas Mol Biol. 1975;43:103-218 [891.001]
  • [Cites] Exp Parasitol. 1995 Feb;80(1):8-14 [7821414.001]
  • [Cites] Methods Enzymol. 1983;91:95-119 [6855607.001]
  • [Cites] Parasitol Res. 2002 Oct;88(10):946-9 [12209338.001]
  • [Cites] Exp Parasitol. 1970 Dec;28(3):557-65 [4323162.001]
  • [Cites] Int J Parasitol. 1998 Mar;28(3):413-8 [9559359.001]
  • [Cites] Prog Neurobiol. 1993 Jul;41(1):31-91 [8321908.001]
  • [Cites] J Biol Chem. 1985 Jan 25;260(2):880-6 [3968070.001]
  • [Cites] J Biol Chem. 1981 Sep 10;256(17):9316-23 [6790550.001]
  • [Cites] Mol Biochem Parasitol. 1987 Dec;26(3):257-65 [3123928.001]
  • [Cites] Vet Res. 1997 May-Jun;28(3):287-93 [9208448.001]
  • [Cites] J Neurochem. 1983 Jul;41(1):30-46 [6864228.001]
  • [Cites] Res Vet Sci. 1989 May;46(3):363-6 [2740631.001]
  • [Cites] Parasitology. 1997 Dec;115 ( Pt 6):653-60 [9488877.001]
  • [Cites] Mol Biochem Parasitol. 1991 Dec;49(2):205-14 [1775164.001]
  • [Cites] J Clin Microbiol. 1985 Sep;22(3):329-32 [2995435.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Z Parasitenkd. 1978 Aug 7;56(3):267-73 [211748.001]
  • [Cites] Anal Biochem. 1993 Jan;208(1):44-8 [8434794.001]
  • [Cites] Mol Biochem Parasitol. 1981 Dec;4(3-4):171-82 [7329440.001]
  • [Cites] Parasitology. 1991;102 Suppl:S7-29 [1711668.001]
  • [Cites] Int J Parasitol. 1973 Sep;3(5):589-97 [4795374.001]
  • [Cites] Vet Parasitol. 1996 Apr;62(3-4):291-305 [8686175.001]
  • [Cites] Parasitology. 1993 Dec;107 ( Pt 5):553-7 [8295794.001]
  • [Cites] Biochem Pharmacol. 1961 Jul;7:88-95 [13726518.001]
  • (PMID = 14672450.001).
  • [ISSN] 0165-7380
  • [Journal-full-title] Veterinary research communications
  • [ISO-abbreviation] Vet. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anthelmintics; 0 / Cholinesterase Inhibitors; 2880D3468G / Levamisole; 402-40-4 / Benzenaminium, 4,4'-(3-oxo-1,5-pentanediyl)bis(N,N-dimethyl-N-2-propenyl-), Dibromide; 513-00-8 / Tetraisopropylpyrophosphamide; 9002-93-1 / Octoxynol; EC 3.1.1.8 / Cholinesterases; EC 3.1.3.1 / Alkaline Phosphatase; EC 3.1.3.2 / Acid Phosphatase
  •  go-up   go-down


15. Merriweather A, Guenzler V, Brenner M, Unnasch TR: Characterization and expression of enzymatically active recombinant filarial prolyl 4-hydroxylase. Mol Biochem Parasitol; 2001 Sep 3;116(2):185-97
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adult and embryonic Brugia malayi are shown to be susceptible to inhibitors of vertebrate prolyl 4-hydroxylase, with exposed parasites exhibiting pathologies consistent with a disruption in cuticle biosynthesis.
  • Expressed sequence tag (EST) analysis and developmental polymerase chain reaction (PCR) studies demonstrated that Ov-phy-1 was expressed in L3 and adult parasites.
  • [MeSH-minor] Amino Acid Sequence. Animals. Blotting, Southern. Brugia malayi / drug effects. Enzyme Inhibitors / pharmacology. Female. Humans. Isoenzymes / genetics. Molecular Sequence Data. Open Reading Frames. Phylogeny. Polymerase Chain Reaction. Procollagen / metabolism. Pyrones / pharmacology. Recombinant Proteins / metabolism. Sequence Alignment

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11522351.001).
  • [ISSN] 0166-6851
  • [Journal-full-title] Molecular and biochemical parasitology
  • [ISO-abbreviation] Mol. Biochem. Parasitol.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ AF369787/ AF369788/ AF369789
  • [Grant] United States / NIAID NIH HHS / AI / N01-AI-65283
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Isoenzymes; 0 / Procollagen; 0 / Pyrones; 0 / Recombinant Proteins; 500-05-0 / coumalic acid; EC 1.14.11.2 / Procollagen-Proline Dioxygenase
  •  go-up   go-down


16. Diviné M, Casassus P, Koscielny S, Bosq J, Sebban C, Le Maignan C, Stamattoulas A, Dupriez B, Raphaël M, Pico JL, Ribrag V, GELA, GOELAMS: Burkitt lymphoma in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocol. Ann Oncol; 2005 Dec;16(12):1928-35
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt lymphoma in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocol.
  • BACKGROUND: We conducted a phase II study to evaluate in 72 adult patients the efficacy of the intensive LMB chemotherapy regimen, previously reported by the Société Française d'Oncologie Pédiatrique for children with Burkitt lymphoma and L3 acute lymphoblastic leukemia.
  • Group B (not eligible for groups A or C) received five courses of chemotherapy comprising high-dose methotrexate, infusional cytarabine and intrathecal (IT) methotrexate.
  • CONCLUSION: Patients with advanced-stage Burkitt lymphoma, including those with bone marrow and/or central nervous system involvement, can be cured with a short-term intensive chemotherapy regime tailored to the tumor burden.

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16284057.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q573I9DVLP / Leucovorin; VB0R961HZT / Prednisone; WI4X0X7BPJ / Hydrocortisone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down






Advertisement